1.
Neurofilament Light Chain Determination: Referee for Future Vitamin D3 Supplementation in Multiple Sclerosis? Goischke HK.
Neuroimmunomodulation. 2022 Feb 9:1-3. doi: 10.1159/000521266. Online ahead of print.
PMID: 35139509 No abstract available.
2.
Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy. Catalá E, Iacoboni G, Vidal-Jordana Á, Oristrell G, Carpio C, Vilaseca A, Cabirta A, Bosch F, Tintoré M, Barba P.
Hematol Oncol. 2022 Feb 9. doi: 10.1002/hon.2976. Online ahead of print.
PMID: 35139240
3.
Attrition Within Digital Health Interventions for People With Multiple Sclerosis: Systematic Review and Meta-analysis. Bevens W, Weiland T, Gray K, Jelinek G, Neate S, Simpson-Yap S.
J Med Internet Res. 2022 Feb 9;24(2):e27735. doi: 10.2196/27735.
PMID: 35138262 Review.
4.
Itaconate and fumarate derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in macrophages. Hoyle C, Green JP, Allan SM, Brough D, Lemarchand E.
Immunology. 2022 Feb 9. doi: 10.1111/imm.13454. Online ahead of print.
PMID: 35137954
5.
Tumor necrosis factor‑α in systemic lupus erythematosus: Structure, function and therapeutic implications (Review). Ghorbaninezhad F, Leone P, Alemohammad H, Najafzadeh B, Nourbakhsh NS, Prete M, Malerba E, Saeedi H, Tabrizi NJ, Racanelli V, Baradaran B.
Int J Mol Med. 2022 Apr;49(4):43. doi: 10.3892/ijmm.2022.5098. Epub 2022 Feb 9.
PMID: 35137914
6.
Productivity loss among people with early multiple sclerosis: A Canadian study. Rodriguez Llorian E, Zhang W, Khakban A, Patten S, Traboulsee A, Oh J, Kolind S, Prat A, Tam R, Lynd LD.
Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070. Online ahead of print.
PMID: 35137613
7.
First Wave of COVID-19 Pandemic in Italy: Data and Evidence. Bezzini D, Schiavetti I, Manacorda T, Franzone G, Battaglia MA.
Adv Exp Med Biol. 2021;1353:91-113. doi: 10.1007/978-3-030-85113-2_6.
PMID: 35137370
8.
Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate. Liu S, Paknejad N, Zhu L, Kihara Y, Ray M, Chun J, Liu W, Hite RK, Huang XY.
Nat Commun. 2022 Feb 8;13(1):731. doi: 10.1038/s41467-022-28417-2.
PMID: 35136060
9.
The C-type lectin receptor Clec1A plays an important role in the development of experimental autoimmune encephalomyelitis by enhancing antigen presenting ability of dendritic cells and inducing inflammatory cytokine IL-17. Makusheva Y, Chung SH, Akitsu A, Maeda N, Maruhashi T, Ye XQ, Kaifu T, Saijo S, Sun H, Han W, Tang C, Iwakura Y.
Exp Anim. 2022 Feb 8. doi: 10.1538/expanim.21-0191. Online ahead of print.
PMID: 35135958
10.
Unusual primary central nervous system T-cell/histiocyte-rich large B-cell lymphoma: a case report. Toro J, Patiño J, Flórez A, Rivera JS.
BMJ Case Rep. 2022 Feb 8;15(2):e246355. doi: 10.1136/bcr-2021-246355.
PMID: 35135790
11.
Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis. Salazar IL, Lourenço AST, Manadas B, Baldeiras I, Ferreira C, Teixeira AC, Mendes VM, Novo AM, Machado R, Batista S, Macário MDC, Grãos M, Sousa L, Saraiva MJ, Pais AACC, Duarte CB.
J Neuroinflammation. 2022 Feb 8;19(1):44. doi: 10.1186/s12974-022-02404-2.
PMID: 35135578
12.
CNS endothelial derived extracellular vesicles are biomarkers of active disease in multiple sclerosis. Mazzucco M, Mannheim W, Shetty SV, Linden JR.
Fluids Barriers CNS. 2022 Feb 8;19(1):13. doi: 10.1186/s12987-021-00299-4.
PMID: 35135557
13.
Exploring the role of stem cell therapy in treating neurodegenerative diseases: Challenges and current perspectives. Puranik N, Arukha AP, Yadav SK, Yadav D, Jin JO.
Curr Stem Cell Res Ther. 2021 Aug 9. doi: 10.2174/1574888X16666210810103838. Online ahead of print.
PMID: 35135462
14.
ACKR1 favors transcellular over paracellular T-cell diapedesis across the blood-brain barrier in neuroinflammation in vitro. Marchetti L, Francisco D, Soldati S, Haghayegh Jahromi N, Barcos S, Gruber I, Pareja JR, Thiriot A, von Andrian U, Deutsch U, Lyck R, Bruggmann R, Engelhardt B.
Eur J Immunol. 2022 Jan;52(1):161-177. doi: 10.1002/eji.202149238. Epub 2021 Sep 30.
PMID: 34524684
1.
The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcome. Cooze BJ, Dickerson M, Loganathan R, Watkins LM, Grounds E, Pearson BR, Bevan RJ, Morgan BP, Magliozzi R, Reynolds R, Neal JW, Howell OW.
Brain Pathol. 2022 Feb 7:e13054. doi: 10.1111/bpa.13054. Online ahead of print.
PMID: 35132719
2.
Cytokine Storm and Failed Resolution in COVID-19: Taking a Cue from Multiple Sclerosis. Zahoor I, Li Y, Rattan R, Giri S.
Adv Exp Med Biol. 2021;1352:211-222. doi: 10.1007/978-3-030-85109-5_13.
PMID: 35132603
3.
Strong evidence that Epstein-Barr virus infection triggers multiple sclerosis. Welberg L.
Nat Neurosci. 2022 Feb 7. doi: 10.1038/s41593-022-01017-5. Online ahead of print.
PMID: 35132232 No abstract available.
4.
Epstein-Barr virus and multiple sclerosis. Yates D.
Nat Rev Neurosci. 2022 Feb 7. doi: 10.1038/s41583-022-00566-9. Online ahead of print.
PMID: 35132220 No abstract available.
5.
Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: protocol of a randomised parallel multicentre trial. Seebacher B, Helmlinger B, Pinter D, Ehling R, Hegen H, Ropele S, Reishofer G, Enzinger C, Brenneis C, Deisenhammer F.
BMJ Open. 2022 Feb 7;12(2):e056666. doi: 10.1136/bmjopen-2021-056666.
PMID: 35131834
6.
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression. Tao C, Simpson-Yap S, Taylor B, Blizzard L, Lucas R, Ponsonby AL, Broadley S, van der Mei I; AusLong/Ausimmune Investigators Group.
Mult Scler Relat Disord. 2022 Jan 25;59:103561. doi: 10.1016/j.msard.2022.103561. Online ahead of print.
PMID: 35131728
7.
Improvement of gait and balance in patients with multiple sclerosis after multidisciplinary physical rehabilitation: Analysis of real-world data in Russia. Stepanova A, Makshakov G, Kulyakhtin A, Kalinin I, Feys P, Evdoshenko E.
Mult Scler Relat Disord. 2022 Feb 3;59:103640. doi: 10.1016/j.msard.2022.103640. Online ahead of print.
PMID: 35131727 Review. No abstract available.
8.
Interleukin 32 Gene Promoter Polymorphism: A genetic risk factor for Multiple Sclerosis in Kashmiri population. Parray Z, Zargar MH, Dar WR, Asimi R, Yaqoob A, Raina A, Ganie H, Wani M, Shah Z.
Gene. 2022 Feb 4:146261. doi: 10.1016/j.gene.2022.146261. Online ahead of print.
PMID: 35131367
9.
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis. Vigne S, Duc D, Peter B, Rebeaud J, Yersin Y, Ruiz F, Bressoud V, Collet TH, Pot C.
J Neuroinflammation. 2022 Feb 7;19(1):42. doi: 10.1186/s12974-022-02409-x.
PMID: 35130916
10.
A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression. Sesel AL, Sharpe L, Beadnall HN, Barnett MH, Szabo M, Naismith SL.
Mult Scler. 2022 Feb 7:13524585211068002. doi: 10.1177/13524585211068002. Online ahead of print.
PMID: 35130768
1.
Next-generation sequencing of the whole mitochondrial genome identifies functionally deleterious mutations in patients with multiple sclerosis. Al-Kafaji G, Bakheit HF, AlAli F, Fattah M, Alhajeri S, Alharbi MA, Daif A, Alsabbagh MM, Alwehaidah MS, Bakhiet M.
PLoS One. 2022 Feb 7;17(2):e0263606. doi: 10.1371/journal.pone.0263606. eCollection 2022.
PMID: 35130313
2.
The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents. O’Mahony J, Banwell B, Laporte A, Brown A, Bolongaita L, Bar-Or A, Yeh EA, Marrie RA.
Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521. Online ahead of print.
PMID: 35130081
3.
The Tyrosine Kinase Tec Regulates Effector Th17 Differentiation, Pathogenicity, and Plasticity in T-Cell-Driven Intestinal Inflammation. Sandner L, Alteneder M, Zhu C, Hladik A, Högler S, Rica R, Van Greuningen LW, Sharif O, Sakaguchi S, Knapp S, Kenner L, Trauner M, Ellmeier W, Boucheron N.
Front Immunol. 2021 Dec 21;12:750466. doi: 10.3389/fimmu.2021.750466. eCollection 2021.
PMID: 35003062 Free PMC article.
4.
Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis. Poch T, Krause J, Casar C, Liwinski T, Glau L, Kaufmann M, Ahrenstorf AE, Hess LU, Ziegler AE, Martrus G, Lunemann S, Sebode M, Li J, Schwinge D, Krebs CF, Franke A, Friese MA, Oldhafer KJ, Fischer L, Altfeld M, Lohse AW, Huber S, Tolosa E, Gagliani N, Schramm C.
J Hepatol. 2021 Aug;75(2):414-423. doi: 10.1016/j.jhep.2021.03.016. Epub 2021 Mar 24.
PMID: 33774059 Free PMC article.
5.
Inter-center agreement in the interpretation of oligoclonal bands. Mariotto S, Ferraro D, Soldani F, Alberti D, Bedin R, Sola P, Gastaldi M, Franciotta D, Ferrari S.
Clin Chem Lab Med. 2020 Sep 28;59(3):e91-e94. doi: 10.1515/cclm-2020-1037. Print 2021 Feb 23.
PMID: 32986610 No abstract available.
6.
Application of Next-Generation Sequencing in Neurodegenerative Diseases: Opportunities and Challenges. Shademan B, Biray Avci C, Nikanfar M, Nourazarian A.
Neuromolecular Med. 2021 Jun;23(2):225-235. doi: 10.1007/s12017-020-08601-7. Epub 2020 May 12.
PMID: 32399804 Review.
1.
MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes. Bakhshi S, Shamsi S.
Int Immunopharmacol. 2022 Feb 3;106:108595. doi: 10.1016/j.intimp.2022.108595. Online ahead of print.
PMID: 35124417 Review.
2.
Serum HGF and APN2 are associated with disability worsening in SPMS. Tottenham I, Koch M, Camara-Lemarroy C.
J Neuroimmunol. 2021 Dec 30;364:577803. doi: 10.1016/j.jneuroim.2021.577803. Online ahead of print.
PMID: 35124365
3.
Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort. Carnero Contentti E, Eizaguirre MB, López PA, Rojas JI, Tkachuk V, Alonso R.
Mult Scler Relat Disord. 2022 Jan 31;59:103647. doi: 10.1016/j.msard.2022.103647. Online ahead of print.
PMID: 35124305
4.
Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis. Zanotto T, Sosnoff JJ, Ofori E, Golan D, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Wilken J, Muratori L, Covey TJ, Gudesblatt M.
Mult Scler Relat Disord. 2022 Jan 30;59:103645. doi: 10.1016/j.msard.2022.103645. Online ahead of print.
PMID: 35124304
5.
Perceived stress in multiple sclerosis patients: Relationship with mood states and pain experience. Khedr MA, El Sayed HG, El Wakil A.
Mult Scler Relat Disord. 2022 Feb 1;59:103650. doi: 10.1016/j.msard.2022.103650. Online ahead of print.
PMID: 35124303
6.
Using myelin water imaging to link underlying pathology to clinical function in multiple sclerosis: A scoping review. Edwards EM, Wu W, Fritz NE.
Mult Scler Relat Disord. 2022 Jan 30;59:103646. doi: 10.1016/j.msard.2022.103646. Online ahead of print.
PMID: 35124302 Review.
7.
Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group. Ciampi E, Guerra-Posada C, Treviño-Frenk I, Cortes-Enriquez F, Correa-Díaz EP, Steinberg J, Fragoso Y, Garcia Bonitto J, Macias MA, Novarro N, Carra A, Vizcarra D, Vrech C, Carcamo C.
Mult Scler Relat Disord. 2022 Jan 30;59:103649. doi: 10.1016/j.msard.2022.103649. Online ahead of print.
PMID: 35124301
8.
Impaired sequential but preserved motor memory consolidation in multiple sclerosis disease. Borragán G, Benoit CE, Schul N, Strauss M, De Schepper M, Roekens V, Peigneux P.
Neuroscience. 2022 Feb 3:S0306-4522(21)00653-9. doi: 10.1016/j.neuroscience.2021.12.029. Online ahead of print.
PMID: 35124165
9.
Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease. Rath J, Foesleitner O, Haider L, Bickel H, Leutmezer F, Polanec S, Arnoldner MA, Sunder-Plassmann G, Prayer D, Berger T, Rommer P, Kasprian G.
Orphanet J Rare Dis. 2022 Feb 5;17(1):37. doi: 10.1186/s13023-022-02187-y.
PMID: 35123534
1.
Hypogonadism in men with multiple sclerosis: Prevalence and clinical associations. Diaconu C, Lee AJ, Onomichi K, De Jager RL, Riley C, Levine L, Vargas W, Shelter K, De Jager PL, Farber RS.
Mult Scler Relat Disord. 2022 Jan 10;59:103508. doi: 10.1016/j.msard.2022.103508. Online ahead of print.
PMID: 35123293
2.
Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes. Diržiuvienė B, Mickevičienė D.
Mult Scler Relat Disord. 2022 Jan 31;59:103558. doi: 10.1016/j.msard.2022.103558. Online ahead of print.
PMID: 35123292
3.
Wilcoxon-Mann-Whitney odds ratio: A statistical measure for ordinal outcomes such as EDSS. Howard CW, Zou G, Morrow SA, Fridman S, Racosta JM.
Mult Scler Relat Disord. 2022 Jan 10;59:103516. doi: 10.1016/j.msard.2022.103516. Online ahead of print.
PMID: 35123291
4.
Dialectical behavior therapy skills training for individuals with multiple sclerosis and their support partners: A pilot randomized controlled trial. Hughes AJ, Botanov Y, Beier M.
Mult Scler Relat Disord. 2022 Jan 8;59:103481. doi: 10.1016/j.msard.2021.103481. Online ahead of print.
PMID: 35123290
5.
Effects of repetitive transcranial magnetic stimulation in multiple sclerosis: A systematic review and meta-analysis. Chen X, Yin L, An Y, Yan H, Zhang T, Lu X, Yan J.
Mult Scler Relat Disord. 2022 Jan 29;59:103564. doi: 10.1016/j.msard.2022.103564. Online ahead of print.
PMID: 35123289 Review.
6.
Elevated levels of IL-32 in cerebrospinal fluid of neuro-Behcet disease: Correlation with NLRP3 inflammasome. Hamzaoui K, Borhani-Haghighi A, Dhifallah IB, Hamzaoui A.
J Neuroimmunol. 2022 Jan 30;365:577820. doi: 10.1016/j.jneuroim.2022.577820. Online ahead of print.
PMID: 35123164
7.
Treatment of multiple sclerosis in children: A brief overview. Nicotera AG, Spoto G, Saia MC, Midiri M, Turriziani L, Amore G, Di Rosa G.
Clin Immunol. 2022 Feb 2:108947. doi: 10.1016/j.clim.2022.108947. Online ahead of print.
PMID: 35123059 Review.
8.
Cathepsin B inhibitor alleviates Th1, Th17, and Th22 transcription factor signaling dysregulation in experimental autoimmune encephalomyelitis. Ansari MA, Nadeem A, Alshammari MA, Attia SM, Bakheet SA, Khan MR, Albekairi TH, Alasmari AF, Alhosaini K, Alqahtani F, Al-Mazroua HA, Ahmad SF.
Exp Neurol. 2022 Feb 2:113997. doi: 10.1016/j.expneurol.2022.113997. Online ahead of print.
PMID: 35122866
9.
Tracking Neural Stem Cells in vivo: Achievements and Limitations. Xue CR, Wang K, Zhang MZ, Wang Z, Song YY, Yu HJ, Hao Y, Guan YT.
Stem Cell Rev Rep. 2022 Feb 5. doi: 10.1007/s12015-022-10333-z. Online ahead of print.
PMID: 35122628 Review.
10.
Successful long-term management of spasticity in people with multiple sclerosis using a software application: Results from a randomized-controlled, multicenter study. Ehling R, Seebacher B, Harsányi A, Ganzbiller N, Papez S, Haider B, Hoertenhuber D, Kranz G, Tarasiewicz R, Spatt J, Moser H, Klein W, Barth C, Kubik W, Kronberger E, Winkler A, Brenneis C.
Eur J Neurol. 2022 Feb 4. doi: 10.1111/ene.15271. Online ahead of print.
PMID: 35122365
11.
Scalp dysesthesia: a neuropathic phenomenon. Ju T, Vander Does A, Yosipovitch G.
J Eur Acad Dermatol Venereol. 2022 Feb 5. doi: 10.1111/jdv.17985. Online ahead of print.
PMID: 35122352 Review.
12.
Ionic mitigation of CD4+ T cell metabolic fitness, Th1 central nervous system autoimmunity and Th2 asthmatic airway inflammation by therapeutic zinc. Krone A, Fu Y, Schreiber S, Kotrba J, Borde L, Nötzold A, Thurm C, Negele J, Franz T, Stegemann-Koniszewski S, Schreiber J, Garbers C, Shukla A, Geffers R, Schraven B, Reinhold D, Dudeck A, Reinhold A, Müller AJ, Kahlfuss S.
Sci Rep. 2022 Feb 4;12(1):1943. doi: 10.1038/s41598-022-04827-6.
PMID: 35121767
13.
Lesion Volume in Relapsing Multiple Sclerosis is Associated with Perivascular Space Enlargement at the Level of the Basal Ganglia. Kolbe SC, Garcia LM, Yu N, Boonstra FM, Clough M, Sinclair B, White O, van der Walt A, Butzkueven H, Fielding J, Law M.
AJNR Am J Neuroradiol. 2022 Feb;43(2):238-244. doi: 10.3174/ajnr.A7398.
PMID: 35121585
14.
The neuroprotective effects and transdifferentiation of astrocytes into dopaminergic neurons of Ginkgolide K on Parkinson’ disease mice. Miao Q, Chai Z, Song LJ, Wang Q, Song GB, Wang J, Yu JZ, Xiao BG, Ma CG.
J Neuroimmunol. 2022 Jan 7;364:577806. doi: 10.1016/j.jneuroim.2022.577806. Online ahead of print.
PMID: 35121334
15.
Lifetime physical activity is associated with gut bacteria and brain health in people with multiple sclerosis: Focus on physical activity intensity. Mokhtarzade M, Molanouri Shamsi M, Abolhasani M, Bakhshi B, Sahraian MA, Hamzeh Shalamzari M, Soudi S.
Mult Scler Relat Disord. 2022 Jan 29;59:103639. doi: 10.1016/j.msard.2022.103639. Online ahead of print.
PMID: 35121248
16.
Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease. AbdelRazek MA, Casasola M, Mollashahi R, Brodski A, Morin S, Augustynowicz A, Jassim S, Matiello M, Sloane J.
Mult Scler Relat Disord. 2022 Jan 21;59:103505. doi: 10.1016/j.msard.2022.103505. Online ahead of print.
PMID: 35121247
17.
Physical exercise may improve problem-solving skills and emotional intelligence in patients with relapsing-remitting multiple sclerosis: A cross-sectional study. Tasci I, Demir CF, Bilek F, Albayrak S.
Mult Scler Relat Disord. 2022 Jan 29;59:103641. doi: 10.1016/j.msard.2022.103641. Online ahead of print.
PMID: 35121246
18.
Identification of miRNAs and their potential effects on multiple sclerosis related pathways using ın silico analysis. Burcin E, Senay VK.
Mult Scler Relat Disord. 2022 Jan 30;59:103642. doi: 10.1016/j.msard.2022.103642. Online ahead of print.
PMID: 35121245
1.
TH17 cells in multiple sclerosis dislodge another brick in the wall. Pillai S.
Sci Immunol. 2022 Feb 4;7(68):eabo2989. doi: 10.1126/sciimmunol.abo2989. Epub 2022 Feb 4.
PMID: 35119940
2.
No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis. Piervincenzi C, Sbardella E, Altieri M, Ianniello A, Pantano P, Pozzilli C, Petsas N.
Neurol Ther. 2022 Feb 4. doi: 10.1007/s40120-022-00328-w. Online ahead of print.
PMID: 35119678
3.
Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity. Chen D, Wolansky I, Imitola J, Malchoff C, Wu R, Dhib-Jalbut S, Bulsara K, Wolansky L.
J Int Med Res. 2022 Feb;50(2):3000605221076977. doi: 10.1177/03000605221076977.
PMID: 35118901
4.
Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS. Alshehri A, Al-Iedani O, Arm J, Gholizadeh N, Billiet T, Lea R, Lechner-Scott J, Ramadan S.
Neuroradiol J. 2022 Feb 4:19714009211067400. doi: 10.1177/19714009211067400. Online ahead of print.
PMID: 35118885
5.
Intertwined like a double helix: A meta-synthesis of the qualitative literature examining the experiences of living with someone with multiple sclerosis. Parkinson A, Brunoro C, Leayr J, Fanning V, Chisholm K, Drew J, Desborough J, Phillips C.
Health Expect. 2022 Feb 4. doi: 10.1111/hex.13432. Online ahead of print.
PMID: 35118764 Review.
6.
Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Jasiak-Zatońska M, Pietrzak A, Wyciszkiewicz A, Więsik-Szewczyk E, Pawlak-Buś K, Leszczyński P, Kozubski W, Michalak S, Kalinowska-Łyszczarz A.
Neurol Neurochir Pol. 2022 Feb 4. doi: 10.5603/PJNNS.a2022.0013. Online ahead of print.
PMID: 35118639
7.
Onychomycosis Caused by Kloeckera apiculata: A Case Report in a Patient with Multiple Sclerosis. Sánchez-Cárdenas CD, Vega-Sánchez DC, González-Suárez TR, Flores-Rivera J, Arenas RG, Corona T.
Skin Appendage Disord. 2022 Jan;8(1):49-52. doi: 10.1159/000518046. Epub 2021 Aug 13.
PMID: 35118131
8.
Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes. Liu QR, Aseer KR, Yao Q, Zhong X, Ghosh P, O’Connell JF, Egan JM.
Front Pharmacol. 2022 Jan 18;12:809965. doi: 10.3389/fphar.2021.809965. eCollection 2021.
PMID: 35115945 Free PMC article. Review.
9.
Neuron to Oligodendrocyte Precursor Cell Synapses: Protagonists in Oligodendrocyte Development and Myelination, and Targets for Therapeutics. Moura DMS, Brennan EJ, Brock R, Cocas LA.
Front Neurosci. 2022 Jan 18;15:779125. doi: 10.3389/fnins.2021.779125. eCollection 2021.
PMID: 35115904 Free PMC article. Review.
10.
Disentangling glial diversity in peripheral nerves at single-nuclei resolution. Yim AKY, Wang PL, Bermingham JR Jr, Hackett A, Strickland A, Miller TM, Ly C, Mitra RD, Milbrandt J.
Nat Neurosci. 2022 Feb 3. doi: 10.1038/s41593-021-01005-1. Online ahead of print.
PMID: 35115729
11.
Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D’Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H.
Nat Rev Neurol. 2022 Feb 3. doi: 10.1038/s41582-021-00616-3. Online ahead of print.
PMID: 35115728 Review.
12.
Mixed pathologies mimicking motor neuron disease: a case report and review of the literature. Dey A, Assaedi E, Johnston W, Kalra S, Das S.
Folia Neuropathol. 2021;59(4):403-408. doi: 10.5114/fn.2021.111486.
PMID: 35114781
13.
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis. Tietz AK, Angstwurm K, Baumgartner T, Doppler K, Eisenhut K, Elisak M, Franke A, Golombeck KS, Handreka R, Kaufmann M, Kraemer M, Kraft A, Lewerenz J, Lieb W, Madlener M, Melzer N, Mojzisova H, Möller P, Pfefferkorn T, Prüss H, Rostásy K, Schnegelsberg M, Schröder I, Siebenbrodt K, Sühs KW, Wickel J, Wandinger KP, Leypoldt F, Kuhlenbäumer G; German Network for Research on Autoimmune Encephalitis (GENERATE).
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 28;8(6):e1085. doi: 10.1212/NXI.0000000000001085. Print 2021 Nov.
PMID: 34584012 Free PMC article.
14.
Retinal Optical Coherence Tomography in Neuromyelitis Optica. Oertel FC, Specovius S, Zimmermann HG, Chien C, Motamedi S, Bereuter C, Cook L, Lana Peixoto MA, Fontanelle MA, Kim HJ, Hyun JW, Palace J, Roca-Fernandez A, Yeaman MR, Smith T, Brandt AU, Paul F.
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 15;8(6):e1068. doi: 10.1212/NXI.0000000000001068. Print 2021 Nov.
PMID: 34526385 Free PMC article.
1.
Identification of multiple sclerosis-related genes regulated by EBV-encoded microRNAs in B cells. Rang X, Liu Y, Wang J, Wang Y, Xu C, Fu J.
Mult Scler Relat Disord. 2022 Jan 25;59:103563. doi: 10.1016/j.msard.2022.103563. Online ahead of print.
PMID: 35114606
2.
Is EBV the cause of multiple sclerosis? Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Gold J.
Mult Scler Relat Disord. 2022 Jan 29;58:103636. doi: 10.1016/j.msard.2022.103636. Online ahead of print.
PMID: 35114510 No abstract available.
3.
Anti-aquaporin-4 immunoglobulin G colorimetric detection by silver nanoparticles. Higa AM, Moraes AS, Shimizu FM, Bueno RG, Peroni LA, Strixino FT, Sousa NAC, Deffune E, Bovolato ALC, Osvaldo NO Jr, Brum DG, Leite FL.
Nanomedicine. 2022 Jan 31:102531. doi: 10.1016/j.nano.2022.102531. Online ahead of print.
PMID: 35114406
4.
Acute cardiovascular conditions in the setting of multiple sclerosis relapse: Practical implications. Polat MO, Yalta K, Yalta T, Ozturk C.
Kardiol Pol. 2022 Feb 3. doi: 10.33963/KP.a2022.0025. Online ahead of print.
PMID: 35114003 No abstract available.
5.
The Long-Term Outcome of Radiofrequency Ablation in Multiple Sclerosis-Related Symptomatic Trigeminal Neuralgia. Mousavi SH, Gehling P, Burchiel KJ.
Neurosurgery. 2022 Jan 11. doi: 10.1227/NEU.0000000000001817. Online ahead of print.
PMID: 35113822
6.
A closer look at the influence of mood and disability on illness intrusiveness in multiple sclerosis. Altaras C, Vissichio N, Miller J, Shagalow S, Foley FW.
Rehabil Psychol. 2022 Feb;67(1):100-109. doi: 10.1037/rep0000393. Epub 2021 Oct 4.
PMID: 35113641
7.
Frequency of ocular manifestations in multiple sclerosis patients admitted in tertiary care hospital in Saudi Arabia. Alharbi A.
Eur Rev Med Pharmacol Sci. 2022 Jan;26(2):637-642. doi: 10.26355/eurrev_202201_27890.
PMID: 35113439
8.
Epidemiological study of multiple sclerosis in Illawarra region. Dal SR, Elphick TL, Fuller K.
Intern Med J. 2022 Feb 3. doi: 10.1111/imj.15704. Online ahead of print.
PMID: 35112760
9.
Gastrointestinal motility disorders in patients with multiple sclerosis: A single-center study. Khanna L, Zeydan B, Kantarci OH, Camilleri M.
Neurogastroenterol Motil. 2022 Feb 3:e14326. doi: 10.1111/nmo.14326. Online ahead of print.
PMID: 35112759
10.
Peripheral helper T cells in the pathogenesis of multiple sclerosis. Holm Hansen R, Højsgaard Chow H, Talbot J, Buhelt S, Nickelsen Hellem MN, Nielsen JE, Sellebjerg FT, von Essen MR.
Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696. Online ahead of print.
PMID: 35112578
11.
Family planning in people with multiple sclerosis: a plain language summary. Bonavita S, Lavorgna L, Worton H, Jack D.
Neurodegener Dis Manag. 2022 Feb 3. doi: 10.2217/nmt-2021-0045. Online ahead of print.
PMID: 35112573 Review.
12.
Perivascular space is associated with brain atrophy in patients with multiple sclerosis. Liu XY, Ma GY, Wang S, Gao Q, Guo C, Wei Q, Zhou X, Chen LP.
Quant Imaging Med Surg. 2022 Feb;12(2):1004-1019. doi: 10.21037/qims-21-705.
PMID: 35111601 Free PMC article.
13.
The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease. Boleto G, Avouac J, Allanore Y.
Ther Adv Musculoskelet Dis. 2022 Jan 29;14:1759720X211066686. doi: 10.1177/1759720X211066686. eCollection 2022.
PMID: 35111241 Free PMC article. Review.
14.
Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55–IL6ST Gene Region in Immature Dendritic Cells. Mena J, Alloza I, Tulloch Navarro R, Aldekoa A, Díez García J, Villanueva Etxebarria A, Lindskog C, Antigüedad A, Boyero S, Mendibe-Bilbao MDM, Álvarez de Arcaya A, Sánchez Menoyo JL, Midaglia L, Villarrubia N, Malhotra S, Montalban X, Villar LM, Comabella M, Vandenbroeck K.
Front Immunol. 2022 Jan 17;12:816930. doi: 10.3389/fimmu.2021.816930. eCollection 2021.
PMID: 35111166 Free PMC article.
15.
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. Iannetta M, Landi D, Cola G, Campogiani L, Malagnino V, Teti E, Coppola L, Di Lorenzo A, Fraboni D, Buccisano F, Grelli S, Mozzani M, Zingaropoli MA, Ciardi MR, Nisini R, Bernardini S, Andreoni M, Marfia GA, Sarmati L.
Front Immunol. 2022 Jan 17;12:796482. doi: 10.3389/fimmu.2021.796482. eCollection 2021.
PMID: 35111162 Free PMC article.
16.
In-Depth Characterization of Somatic and Orofacial Sensitive Dysfunctions and Interfering-Symptoms in a Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mouse Model. Démosthènes A, Sion B, Giraudet F, Moisset X, Daulhac L, Eschalier A, Bégou M.
Front Neurol. 2022 Jan 17;12:789432. doi: 10.3389/fneur.2021.789432. eCollection 2021.
PMID: 35111128 Free PMC article.
17.
Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score. Bsteh G, Hegen H, Riedl K, Altmann P, Di Pauli F, Ehling R, Zulehner G, Rommer P, Leutmezer F, Deisenhammer F, Berger T.
Front Neurol. 2022 Jan 17;12:766956. doi: 10.3389/fneur.2021.766956. eCollection 2021.
PMID: 35111123 Free PMC article.
18.
Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis. Greenlee JE, Carlson NG, Abbatemarco JR, Herdlevær I, Clardy SL, Vedeler CA.
Front Neurol. 2022 Jan 17;12:744653. doi: 10.3389/fneur.2021.744653. eCollection 2021.
PMID: 35111121 Free PMC article. Review.
19.
Mimicking Amyotrophic Lateral Sclerosis: A Case of a Spinal Dural Arteriovenous Fistula. Santos M, Reimão S, de Carvalho M.
Case Rep Neurol. 2021 Dec 27;13(3):802-806. doi: 10.1159/000521030. eCollection 2021 Sep-Dec.
PMID: 35111029 Free PMC article.
20.
EBV linked to multiple sclerosis. Du Toit A.
Nat Rev Microbiol. 2022 Feb 2. doi: 10.1038/s41579-022-00701-4. Online ahead of print.
PMID: 35110729 No abstract available.
21.
Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis. Sánchez-Fernández A, Zandee S, Mastrogiovanni M, Charabati M, Rubbo H, Prat A, López-Vales R.
J Neuroinflammation. 2022 Feb 2;19(1):27. doi: 10.1186/s12974-022-02386-1.
PMID: 35109863
22.
Estimation the medical cost of multiple sclerosis in Iran; 2019-2020. Asadollahi M, Darvishi A, Azimi A, Annabi M, Jafariazar Z, Heshmat R.
BMC Health Serv Res. 2022 Feb 2;22(1):137. doi: 10.1186/s12913-022-07551-z.
PMID: 35109835
23.
Domains and dimensions of family quality of life among families with a member with neurodegenerative diseases. Badia M, Orgaz-Baz B, Vicario-Molina I, Ortega EG, Aza A; NEUROQUALYFAM Group.
Alzheimers Dement. 2021 Dec;17 Suppl 7:e054353. doi: 10.1002/alz.054353.
PMID: 35109485
24.
AIM2 inflammasome mediates hallmark neuropathological alterations and cognitive impairment in a mouse model of vascular dementia. Poh L, Fann D, Wong P, Rajeev V, Selvaraji S, Chen C, Lai MKP, Lim HKL, Arumugam TV.
Alzheimers Dement. 2021 Dec;17 Suppl 3:e051709. doi: 10.1002/alz.051709.
PMID: 35109386
25.
Neuropathologic lesions and comorbidity in Alzheimer disease and related dementias in a heterogeneous clinical population. Godrich D, Richeson P, Schellenberg GD, Scott WK, Montine TJ, Beecham GW.
Alzheimers Dement. 2021 Dec;17 Suppl 3:e056249. doi: 10.1002/alz.056249.
PMID: 35109341
26.
Presence of co-pathology in sporadic early-onset Alzheimer disease versus dominantly inherited Alzheimer disease. Llibre-Guerra JJ, Li Y, Franklin EE, Miller CA, Teich AF, Kofler J, Dickson DW, Ghetti BF, Frosch MP, Halliday GM, McLean C, Lashley T, Gordon BA, Schindler SE, Chen CD, Fagan AM, Benzinger TLS, Wang G, Hassenstab J, Morris JC, Bateman RJ, Perrin RJ, McDade E.
Alzheimers Dement. 2021 Dec;17 Suppl 3:e055045. doi: 10.1002/alz.055045.
PMID: 35109330
27.
Sex differences in the genetic architecture underlying resilience in AD. Eissman JM, Dumitrescu L, Mahoney ER, Mukherjee S, Lee ML, Bush WS, Engelman CD, Lu Q, Fardo DW, Trittschuh EH, Mez J, Kaczorowski CC, Saucedo RA, Mayeux R, Cuccaro ML, Bennett DA, Schneider JA, Crane PK, Jefferson AL, Hohman TJ.
Alzheimers Dement. 2021 Dec;17 Suppl 3:e055010. doi: 10.1002/alz.055010.
PMID: 35109279
28.
Traumatic brain injury with loss of consciousness is associated with amyloid-beta burden and cerebral infarcts in community-dwelling older adults. Agrawal S, Leurgans SE, Barnes LL, Bennett DA, Schneider JA.
Alzheimers Dement. 2021 Dec;17 Suppl 3:e054423. doi: 10.1002/alz.054423.
PMID: 35109073
29.
Corticobasal syndrome associated with a novel Lys694del variant of the TBK1 gene. Seibert K, Smith H, Lapins A, Pytel P, Mastrianni J.
Alzheimers Dement. 2021 Dec;17 Suppl 3:e054756. doi: 10.1002/alz.054756.
PMID: 35109011
30.
Ofatumumab for relapsing forms of multiple sclerosis. Gajofatto A, Orlandi R.
Drugs Today (Barc). 2022 Jan;58(1):9-21. doi: 10.1358/dot.2022.58.1.3353168.
PMID: 35107090 Review.
1.
The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis. Sen MK, Mahns DA, Coorssen JR, Shortland PJ.
Glia. 2022 Feb 2. doi: 10.1002/glia.24148. Online ahead of print.
PMID: 35107839 Review.
2.
Multisystem screening reveals SARS-CoV-2 in neurons of the myenteric plexus and in megakaryocytes. Gray-Rodriguez S, Jensen MP, Otero-Jimenez M, Hanley B, Swann OC, Ward PA, Salguero FJ, Querido N, Farkas I, Velentza-Almpani E, Weir J, Barclay WS, Carroll MW, Jaunmuktane Z, Brandner S, Pohl U, Allinson K, Thom M, Troakes C, Al-Sarraj S, Sastre M, Gveric D, Gentleman S, Roufosse C, Osborn M, Alegre-Abarrategui J.
J Pathol. 2022 Feb 2. doi: 10.1002/path.5878. Online ahead of print.
PMID: 35107828
3.
Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target. Rastegar-Moghaddam SH, Ebrahimzadeh-Bideskan A, Shahba S, Malvandi AM, Mohammadipour A.
Cell Mol Neurobiol. 2022 Feb 2. doi: 10.1007/s10571-022-01200-z. Online ahead of print.
PMID: 35107690 Review.
4.
Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation. Vainio SK, Dickens AM, Matilainen M, López-Picón FR, Aarnio R, Eskola O, Solin O, Anthony DC, Rinne JO, Airas L, Haaparanta-Solin M.
EJNMMI Res. 2022 Feb 2;12(1):6. doi: 10.1186/s13550-022-00878-y.
PMID: 35107664
5.
Health-Related Quality of Life in people with Multiple Sclerosis: How does this Population Compare to Population-based Norms in Different Health Domains? Faraclas E, Lynn J, Lau JD, Merlo A.
J Patient Rep Outcomes. 2022 Feb 2;6(1):12. doi: 10.1186/s41687-022-00415-4.
PMID: 35107657
6.
[New master’s program: multiple sclerosis management]. Voigt I, Stadelmann C, Meuth SG, Schipp B, Flachenecker P, Mäurer M, Funk RHW, Ramisch F, Niemeier J, Ziemssen T.
Wien Med Wochenschr. 2022 Feb 2:1-9. doi: 10.1007/s10354-021-00900-3. Online ahead of print.
PMID: 35107651 Free PMC article. German.
7.
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study. Alcalá C, Quintanilla-Bordás C, Gascón F, Sempere ÁP, Navarro L, Carcelén-Gadea M, Landete L, Mallada J, Cañizares E, Belenguer A, Carratalá S, Domínguez JA, Pérez-Miralles FC, Gil-Perotín S, Gasqué R, Cubas L, Castillo J, Casanova B.
J Neurol. 2022 Feb 2. doi: 10.1007/s00415-022-10989-0. Online ahead of print.
PMID: 35107597
8.
Ofatumumab for relapsing forms of multiple sclerosis. Gajofatto A, Orlandi R.
Drugs Today (Barc). 2022 Jan;58(1):9-21. doi: 10.1358/dot.2022.58.1.3353168.
PMID: 35107090
9.
Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Dalla Costa G, Leocani L, Comi G.
Expert Rev Clin Immunol. 2022 Feb 2. doi: 10.1080/1744666X.2022.2031982. Online ahead of print.
PMID: 35107057
10.
Sustained immunotolerance in multiple sclerosis after stem cell transplant. Visweswaran M, Hendrawan K, Massey JC, Khoo ML, Ford CD, Zaunders JJ, Withers B, Sutton IJ, Ma DDF, Moore JJ.
Ann Clin Transl Neurol. 2022 Feb 1. doi: 10.1002/acn3.51510. Online ahead of print.
PMID: 35106961
11.
Significant Association of rs77493513 Polymorphism in 3′-UTR of the NRG1 Gene with the Risk of Multiple Sclerosis Disease. Ghorbani M, Mohamadynejad P, Moghanibashi M.
Metab Brain Dis. 2022 Feb 2. doi: 10.1007/s11011-022-00922-9. Online ahead of print.
PMID: 35106689
12.
COVID-19 hospitalizations, intensive care unit stays, ventilation and death among patients with immune mediated inflammatory diseases compared to controls. Eder L, Croxford R, Drucker AM, Mendel A, Kuriya B, Touma Z, Johnson SR, Cook R, Bernatsky S, Haroon N, Widdifield J.
J Rheumatol. 2022 Feb 1:jrheum.211012. doi: 10.3899/jrheum.211012. Online ahead of print.
PMID: 35105713
13.
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Zabalza A, Arrambide G, Tagliani P, Cárdenas-Robledo S, Otero-Romero S, Esperalba J, Fernandez-Naval C, Trocoli Campuzano J, Martínez Gallo M, Castillo M, Bonastre M, Resina Sallés M, Beltran J, Carbonell-Mirabent P, Rodríguez-Barranco M, López-Maza S, Melgarejo Otálora PJ, Ruiz-Ortiz M, Pappolla A, Rodríguez Acevedo B, Midaglia L, Vidal-Jordana A, Cobo-Calvo A, Tur C, Galán I, Castilló J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Tintore M, Montalban X.
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2):e1143. doi: 10.1212/NXI.0000000000001143. Print 2022 Mar.
PMID: 35105687
14.
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression. Preziosa P, Pagani E, Meani A, Moiola L, Rodegher M, Filippi M, Rocca MA.
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2):e1139. doi: 10.1212/NXI.0000000000001139. Print 2022 Mar.
PMID: 35105685
15.
VITAMIN D AND OPHTHALMOPATHIAS. A REVIEW. Hribová P, Sotak Š.
Cesk Slov Oftalmol. 2022 Winter;2(Ahead of Print):1001-1004.
PMID: 35105147 English.
1.
How patients with multiple sclerosis acquire disability. Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA.
Brain. 2022 Feb 1:awac016. doi: 10.1093/brain/awac016. Online ahead of print.
PMID: 35104840
2.
Accumulation of meningeal lymphocytes correlates with white matter lesion activity in progressive MS. Ahmed SM, Fransen NL, Touil H, Michailidou I, Huitinga I, Gommerman JL, Bar-Or A, Ramaglia V.
JCI Insight. 2022 Feb 1:e151683. doi: 10.1172/jci.insight.151683. Online ahead of print.
PMID: 35104246
3.
Primary Progressive Multiple Sclerosis in a Portuguese Patient With Neurofibromatosis Type 1. Carvalho I, Quintas-Neves M, Pinto J, Santos AF, Pereira J.
Cureus. 2021 Dec 21;13(12):e20561. doi: 10.7759/cureus.20561. eCollection 2021 Dec.
PMID: 35103140 Free PMC article.
4.
Management of bladder dysfunction in multiple sclerosis. A systematic review and meta-analysis of studies regarding bladder rehabilitation. Vecchio M, Chiaramonte R, DI Benedetto P.
Eur J Phys Rehabil Med. 2022 Feb 1. doi: 10.23736/S1973-9087.22.07217-3. Online ahead of print.
PMID: 35102733
5.
Comparing humoral immune response to SARS-CoV2 vaccines in multiple sclerosis and healthy controls: an Austrian prospective multi-center cohort study. Bsteh G, Hegen H, Traxler G, Krajnc N, Leutmezer F, Di Pauli F, Kornek B, Rommer P, Zulehner G, Dürauer S, Bauer A, Kratzwald S, Klotz S, Winklehner M, Deisenhammer F, Guger M, Höftberger R, Berger T.
Eur J Neurol. 2022 Feb 1. doi: 10.1111/ene.15265. Online ahead of print.
PMID: 35102646
6.
Intersecting kinematic encoding and readout of intention in autism. Montobbio N, Cavallo A, Albergo D, Ansuini C, Battaglia F, Podda J, Nobili L, Panzeri S, Becchio C.
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2114648119. doi: 10.1073/pnas.2114648119.
PMID: 35101921
7.
Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex. Hulshof HM, Kuijf HJ, Kotulska K, Curatolo P, Weschke B, Riney K, Krsek P, Feucht M, Nabbout R, Lagae L, Jansen A, Otte WM, Lequin MH, Sijko K, Benvenuto A, Hertzberg C, Benova B, Scholl T, De Ridder J, Aronica EA, Kwiatkowski DJ, Jozwiak S, Jurkiewicz E, Braun K, Jansen FE; EPISTOP consortium.
Neurology. 2022 Jan 31:10.1212/WNL.0000000000200027. doi: 10.1212/WNL.0000000000200027. Online ahead of print.
PMID: 35101906
8.
High-density lipoprotein reduces microglia activation and protects against experimental autoimmune encephalomyelitis in mice. Hong S, Niu M, Meng D, Li A, Dong Q, Zhang J, Tian X, Lu S, Wang Y.
Int Immunopharmacol. 2022 Jan 28;105:108566. doi: 10.1016/j.intimp.2022.108566. Online ahead of print.
PMID: 35101849
9.
Effects of neurodynamic interventions on pain sensitivity and function in patients with multiple sclerosis: a randomized clinical trial. de Dios Pérez-Bruzón J, Fernández-de-Las-Peñas C, Cleland JA, Plaza-Manzano G, Ortega-Santiago R.
Physiotherapy. 2021 Apr 22;115:36-45. doi: 10.1016/j.physio.2021.04.004. Online ahead of print.
PMID: 35101724
10.
TDP-43 pathology: from noxious assembly to therapeutic removal. Keating SS, San Gil R, Swanson MEV, Scotter EL, Walker AK.
Prog Neurobiol. 2022 Jan 28:102229. doi: 10.1016/j.pneurobio.2022.102229. Online ahead of print.
PMID: 35101542 Review.
11.
Myotubularin-related protein protects against neuronal degeneration mediated by oxidative stress or infection. Kaur S, Sang Y, Aballay A.
J Biol Chem. 2022 Jan 28:101614. doi: 10.1016/j.jbc.2022.101614. Online ahead of print.
PMID: 35101447
12.
Evaluation of a program for training psychologists in an acceptance and commitment therapy resilience intervention for people with multiple sclerosis: a single-arm longitudinal design with a nested qualitative study. Giovannetti AM, Messmer Uccelli M, Solari A, Pakenham KI.
Disabil Rehabil. 2022 Feb 1:1-13. doi: 10.1080/09638288.2022.2025926. Online ahead of print.
PMID: 35100924
13.
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V.
Lancet Neurol. 2022 Feb;21(2):189-202. doi: 10.1016/S1474-4422(21)00463-4.
PMID: 35065041 Review.
1.
RPP25 as a Prognostic-Related Biomarker That Correlates With Tumor Metabolism in Glioblastoma. Xiao D, Wu J, Zhao H, Jiang X, Nie C.
Front Oncol. 2022 Jan 12;11:714904. doi: 10.3389/fonc.2021.714904. eCollection 2021.
PMID: 35096558 Free PMC article.
2.
Defining routine fatigue care in Multiple Sclerosis in the United Kingdom: What treatments are offered and who gets them? Picariello F, Freeman J, Moss-Morris R.
Mult Scler J Exp Transl Clin. 2022 Jan 20;8(1):20552173211072274. doi: 10.1177/20552173211072274. eCollection 2022 Jan-Mar.
PMID: 35096412 Free PMC article.
3.
Smouldering multiple sclerosis: the ‘real MS’. Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobeus E, Jensen MB, García-Domínguez JM, Sousa L, De Rossi N, Hupperts R, Fenu G, Bodini B, Kuusisto HM, Stankoff B, Lycke J, Airas L, Granziera C, Scalfari A.
Ther Adv Neurol Disord. 2022 Jan 25;15:17562864211066751. doi: 10.1177/17562864211066751. eCollection 2022.
PMID: 35096143 Free PMC article. Review.
4.
Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Ng HS, Graf J, Zhu F, Kingwell E, Aktas O, Albrecht P, Hartung HP, Meuth SG, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.
Front Immunol. 2022 Jan 13;12:794075. doi: 10.3389/fimmu.2021.794075. eCollection 2021.
PMID: 35095869 Free PMC article.
5.
Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II. Tang L, Li G, Zheng Y, Hou C, Gao Y, Hao Y, Gao Z, Mo R, Li Y, Shen B, Wang R, Wang Z, Han G.
Front Immunol. 2022 Jan 13;12:770402. doi: 10.3389/fimmu.2021.770402. eCollection 2021.
PMID: 35095844 Free PMC article.
6.
Single-Cell Transcriptome Profiling Unravels Distinct Peripheral Blood Immune Cell Signatures of RRMS and MOG Antibody-Associated Disease. Liu J, Yang X, Pan J, Wei Z, Liu P, Chen M, Liu H.
Front Neurol. 2022 Jan 14;12:807646. doi: 10.3389/fneur.2021.807646. eCollection 2021.
PMID: 35095746 Free PMC article.
7.
Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes. Racke MK, Frohman EM, Frohman T.
Front Neurol. 2022 Jan 13;12:799698. doi: 10.3389/fneur.2021.799698. eCollection 2021.
PMID: 35095742 Free PMC article. Review.
8.
Effect of Deep Brain Stimulation on Cerebellar Tremor Compared to Non-Cerebellar Tremor Using a Wearable Device in a Patient With Multiple Sclerosis: Case Report. Xie T, Padmanaban M, Javed A, Satzer D, Towle TE, Warnke P, Towle VL.
Front Hum Neurosci. 2022 Jan 13;15:754091. doi: 10.3389/fnhum.2021.754091. eCollection 2021.
PMID: 35095448 Free PMC article.
9.
Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings in Multiple Sclerosis Patients. Balıkçı A, Parmak Yener N, Seferoğlu M.
Neuroophthalmology. 2021 Aug 20;46(1):19-33. doi: 10.1080/01658107.2021.1963787. eCollection 2022.
PMID: 35095132
10.
Update on Optic Neuritis: An International View. Hickman SJ, Petzold A.
Neuroophthalmology. 2021 Aug 31;46(1):1-18. doi: 10.1080/01658107.2021.1964541. eCollection 2022.
PMID: 35095131 Review.
11.
[A patient with multiple sclerosis who developed bilateral optic neuritis and central trigeminal myelin lesion]. Shimizu F, Mizumoto Y, Kanda T.
Rinsho Shinkeigaku. 2022 Jan 31. doi: 10.5692/clinicalneurol.cn-001658. Online ahead of print.
PMID: 35095049 Japanese.
12.
Alterations of host-gut microbiome interactions in multiple sclerosis. Cantoni C, Lin Q, Dorsett Y, Ghezzi L, Liu Z, Pan Y, Chen K, Han Y, Li Z, Xiao H, Gormley M, Liu Y, Bokoliya S, Panier H, Suther C, Evans E, Deng L, Locca A, Mikesell R, Obert K, Newland P, Wu Y, Salter A, Cross AH, Tarr PI, Lovett-Racke A, Piccio L, Zhou Y.
EBioMedicine. 2022 Jan 25:103798. doi: 10.1016/j.ebiom.2021.103798. Online ahead of print.
PMID: 35094961
13.
Experiences of people with multiple sclerosis participating in a social cognitive behavior change physical activity intervention. Russell N, Gallagher S, Msetfi RM, Hayes S, Motl RW, Coote S.
Physiother Theory Pract. 2022 Jan 31:1-9. doi: 10.1080/09593985.2022.2030828. Online ahead of print.
PMID: 35094662
14.
DNA methylation changes in glial cells of the normal-appearing white matter in Multiple Sclerosis patients. Kular L, Ewing E, Needhamsen M, Pahlevan Kakhki M, Covacu R, Gomez-Cabrero D, Brundin L, Jagodic M.
Epigenetics. 2022 Jan 30:1-20. doi: 10.1080/15592294.2021.2020436. Online ahead of print.
PMID: 35094644
Napsat komentář
Pro přidávání komentářů se musíte nejdříve přihlásit.